Hui Shao

Hui Shao,

Assistant Professor

Department: Pharmaceutical Outcomes & Policy
Business Phone: (352) 294-8323
Business Email: hui.shao@ufl.edu

Teaching Profile

Courses Taught
2020-2023
PHA5267 Prin Pharm-Economics
2021-2023
PHA6940 Supervised Teaching
2021-2023
PHA6971 Research for Master’s Thesis
2020-2023
PHA6935 Selected Topics in Pharmacy
2020-2023
PHA6910 Supervised Research
2021-2023
PHA6805 Applied Data Interpretation and Reporting of Findings in Pharmacy
2020-2023
PHA7979 Advanced Research
2021-2023
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2021-2022
PHA6936 Advanced Topics in Pharmaceutical Sciences
2021-2022
PHA6937 Topics in Pharmaceutical Administration
2020-2021
PHA7980 Research for Doctoral Dissertation
2019
PHA5878C Pt Care 3: Cv and Pulm

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-4088-546X

Publications

2023
Changes in racial and ethnic disparities in glucose‐lowering drug utilization and glycated haemoglobin A1c in US adults with diabetes: 2005‐2018
Diabetes, Obesity and Metabolism. 25(2):516-525 [DOI] 10.1111/dom.14894. [PMID] 36251173.
2023
Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample
Annals of Internal Medicine. [DOI] 10.7326/m22-3051.
2022
Economic Evaluation of the $35 Insulin Copay Cap Policy in Medicare and Its Implication for Future Interventions
Diabetes Care. 45(11):e161-e162 [DOI] 10.2337/dc22-1230. [PMID] 36099174.
2022
Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM‐CURE risk score
Diabetes, Obesity and Metabolism. 24(11):2203-2211 [DOI] 10.1111/dom.14806.
2022
Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare
Diabetes Care. 45(8):1814-1821 [DOI] 10.2337/dc21-2601. [PMID] 35700384.
2022
Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes
Diabetes Care. 45(2):e32-e33 [DOI] 10.2337/dc21-1800.
2021
Trends in Total and Out-of-pocket Payments for Insulin Among Privately Insured U.S. Adults With Diabetes From 2005 to 2018
Diabetes Care. 44(10):e180-e182 [DOI] 10.2337/dc20-2529.
2021
Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018
Diabetes Care. 44(4):925-934 [DOI] 10.2337/dc20-2871.
2020
Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298–2306
Diabetes Care. 43(2):e25-e25 [DOI] 10.2337/dc19-1891. [PMID] 31959647.
2020
Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005–2007 and 2015–2017
Diabetes Care. 43(10):2396-2402 [DOI] 10.2337/dc19-2273. [PMID] 32737138.
2020
Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study
Diabetes Care. 43(11):2847-2852 [DOI] 10.2337/dc20-0465. [PMID] 32887705.
2020
Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors
Diabetes Care. 43(7):1530-1536 [DOI] 10.2337/dc20-0227. [PMID] 32345650.
2019
Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis
Diabetes Care. 42(11):2136-2142 [DOI] 10.2337/dc19-0381.

Grants

Sep 2022 – Dec 2022
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2022 – Dec 2022
Assessing Barriers and Facilitators for Participating Structured Lifestyle Intervention and Its Real-world Effectiveness and Cost-effectiveness among US Veterans
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020 ACTIVE
Using Real-world Data to Assess the Burden of Diabetes in Children and Adolescents in Florida
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020 – Sep 2022
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV via CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2020 – Jul 2021
Simulating Long-Term Outcomes for iGlarlixi using BRAVO Diabetes Model
Role: Principal Investigator
Funding: TULANE UNIV via SANOFI
Jun 2020 – Jun 2022
CDC IPA – Assignment Agreement 20IPA2008335DPG
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION

Contact Details

Phones:
Business:
(352) 294-8323
Emails:
Business:
hui.shao@ufl.edu
Addresses:
Business Mailing:
PO Box 100496
GAINESVILLE FL 32610
Business Street:
PO Box 100496
GAINESVILLE FL 32610

Recent news